Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects. (BIOMOHS)
A Multicenter, Prospective, Randomized Controlled Clinical Trial Assessing the Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects.
A multicenter, prospective, randomized controlled clinical trial assessing the efficacy of a novel cellular, acellular, matrix-like product (CAMP) plus standard of care versus standard of care alone in the management of post-mohs micrographic surgery defects.
調査の概要
状態
詳細な説明
This study will utilize a Prospective, Multicenter, Randomized Controlled Clinical Trial design.
Subjects will be adult patients undergoing Mohs micrographic surgery with resulting post-excisional defects suitable for healing by secondary intention or management with a topical matrix-like product.
Subjects will be randomized to receive:
- CAMP plus Standard of Care (SOC), or
- Control Dressing plus SOC. Randomization will occur after confirmation of final Mohs stage and measurement of the post-excisional defect.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Bennett Sarver
- 電話番号:1-833-865-6300
- メール:info@serenagroups.com
研究場所
-
-
Oklahoma
-
Tulsa、Oklahoma、アメリカ、74132
- 募集
- Southside Dermatology Mohs and Skin Surgery
-
コンタクト:
- Ana Montalva
- 電話番号:(918) 760-0700
- メール:amontalva@dermatologyok.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
The potential subject must be at least 18 years of age or older.
-
The potential subject must have undergone Mohs micrographic surgery for a cutaneous malignancy (e.g., basal cell carcinoma, or squamous cell carcinoma).
-
The potential subject must have a post-Mohs surgical defect that is suitable for treatment with a CAMP product or healing by secondary intention.
-
The surgical site has received standard Mohs excision and hemostasis with no requirement for immediate flap or graft reconstruction as determined by the treating surgeon.
-
If the surgical defect is on the lower extremity, the limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
- Toe-Brachial Index (TBI) ≥ 0.6;
- Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
- Pulse Volume Recording (PVR): biphasic.
-
If the subject has multiple Mohs defects, they must be separated by at least 2 cm. The largest defect satisfying the inclusion and exclusion criteria will be designated as the target wound.
-
The potential subject must agree to attend the weekly study visits required by the protocol.
-
The potential subject must be willing and able to participate in the informed consent process.
Exclusion Criteria:
-
The potential subject is known to have a life expectancy of < 6 months.
-
The potential subject's target wound is not secondary to a Mohs excision.
-
The target wound is infected or there is cellulitis in the surrounding skin.
-
The target wound:
- Exposes tendon, bone, or joint space, and/or
- Requires immediate complex flap or graft reconstruction in the judgment of the surgeon.
-
The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
-
The potential subject has glycated hemoglobin (HbA1c) greater than 10% within 3 months of the initial screening visit.
-
The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Control Dressing + Standard of Care
Standard of care will be cleaning, debridement, ulcer moisture balance, control dressing and offloading. |
Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
|
他の:CAMP + Standard of Care
Membrane Wrap-Lite is a human amniotic membrane tissue allograft derived from human placental tissue. |
Participants will receive weekly applications of Membrane Wrap-Lite and Standard of Care until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete Wound Closure
時間枠:1-6 Weeks
|
The percentage of target wounds achieving complete wound closure in 6 weeks. |
1-6 Weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Closure
時間枠:1-6 Weeks
|
Time to closure for the target wound. |
1-6 Weeks
|
|
Percentage Area Reduction
時間枠:1-6 weeks
|
Percentage wound area reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 weeks
|
|
Procedure-Related Adverse Events
時間枠:1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Wound Volume Reduction
時間枠:1-6 Weeks
|
Percentage wound volume reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 Weeks
|
|
Product or Procedure Adverse Events
時間枠:1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Numeric Pain Scale
時間枠:1-6 weeks
|
Change in pain at the target wound site assessed using a numeric pain scale. 0 being no pain and 10 being the worst pain imaginable. |
1-6 weeks
|
|
Economic Outcomes
時間枠:1-6 Weeks
|
Health economic outcomes, including direct and indirect cost of care. |
1-6 Weeks
|
|
Quality of Life
時間枠:1- 6 Weeks
|
Change in quality of life, using the Wound Quality of Life Questionnaire, with items scored 0-4, where higher scores indicate worse quality of life. |
1- 6 Weeks
|
|
Scare and Cosmetic Outcomes
時間枠:12 Months
|
Scar and cosmetic outcomes at 12 months using the Patient and Observer Scar Assessment Scale (POSAS). 0 being normal and 10 being very different. |
12 Months
|
|
Time to Complete Granulation Tissue
時間枠:1-6 Weeks
|
Time to complete granulation tissue confirmed by independent assessment. |
1-6 Weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Perfusion
時間枠:1-6 Weeks
|
Changes in local perfusion at the surgical site over the 6-week treatment period, assessed via near-infrared spectroscopy. |
1-6 Weeks
|
|
Rate of Recurrence
時間枠:12 Months
|
The rate of recurrence within 12 months of closure when applicable. |
12 Months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- To be determined
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。